

AMENDMENT

In the Claims:

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1-18. CANCELLED

19. (Currently amended) A method of treating or preventing cerebellar neuronal degeneration in a vertebrate subject, comprising administering to a cerebellar lobe of the subject ~~a lentiviral~~ an FIV vector particle, wherein said ~~lentiviral~~ vector particle is produced from ~~a lentiviral~~ an FIV vector comprising a 5' ~~lentiviral~~ FIV LTR, a tRNA binding site, a packaging signal, a promoter operably linked to a polynucleotide encoding a protein of interest, an origin of second strand DNA synthesis and a 3' ~~lentiviral~~ FIV LTR, thereby treating or preventing cerebellar neuronal degeneration in the subject.

20. (Previously presented) A method of treating or preventing cerebellar neuronal degeneration in a vertebrate subject, comprising administering to Purkinje cells of the subject an FIV vector particle, wherein said vector particle is produced from an FIV vector comprising a 5' FIV LTR, a tRNA binding site, a packaging signal, a polynucleotide encoding a protein of interest operably linked to an FIV LTR promoter or a promoter element, an origin of second strand DNA synthesis and a 3' FIV LTR, thereby treating or preventing cerebellar neuronal degeneration in the subject.

21. (Currently amended) A method of treating or preventing a central nervous system disorder in a vertebrate subject, comprising administering to a cerebellar lobe of the subject ~~a lentiviral~~ an FIV vector particle, wherein said vector particle is produced from ~~a lentiviral~~ an FIV vector comprising a 5' ~~lentiviral~~ FIV LTR, a tRNA binding site, a

packaging signal, a promoter operably linked to a polynucleotide encoding a protein of interest, an origin of second strand DNA synthesis and a 3' ~~lentiviral~~ FIV LTR, thereby treating or preventing the central nervous system disorder in the subject.

22. CANCELLED